基立福

最新新闻

• 公司公告
  GRIFOLS SA SPON ADR EA REPR 1/2 ORD SHS EUR0.50 | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
  SEC · 2024/4/10
• FOXO Unit to Acquire Four U.S. Blood Collection Centers From Grifols Subsidiary
  Seeking Alpha · 2026/7/29
• 公司公告
  Shanghai RAAS Blood Products: Special Audit Opinions on Grifols Diagnostic Solutions, Inc.'s Statement of Achievement of the 2019-2023 Performance Commitments
  SZSI · 2024/4/29
• 评级变动
  Berenberg Bank Maintains Grifols(GRFS.US) With Buy Rating, Cuts Target Price to $16.71
  \u5e02\u573a\u8d44\u8baf · 2024/7/30
• Grifols S.A. Q2 2026 Earnings Preview
  Seeking Alpha · 2026/7/28
• 评级变动
  J.P. Morgan Initiates Grifols(GRFS.US) With Hold Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2025/12/8
• 评级变动
  J.P. Morgan Maintains Grifols(GRFS.US) With Hold Rating, Cuts Target Price to $10.3
  \u5e02\u573a\u8d44\u8baf · 2025/6/18
• Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin
  Benzinga · 2026/7/16
• FOXO TECHNOLOGIES INC.'S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
  GlobeNewswire · 2026/7/29
• 公司公告
  GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
  SEC · 2024/4/10
• 公司公告
  Shanghai RAAS Blood Products: Explanation of Grifols Diagnostic Solutions, Inc.'s achievement of its 2019-2023 performance commitments
  SZSI · 2024/4/29
• 公司公告
  GRIFOLS SA SPON ADR EA REPR 1/2 ORD SHS EUR0.50 | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
  SEC · 2024/4/5
• GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS To Go Ex-Dividend On June 30th, 2026 With 0.09363 USD Dividend Per Share
  \u5e02\u573a\u8d44\u8baf · 2026/6/29

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。